Interview with Tabitha Matthews, MSN, APRN-NP, AGACNP-BC, AOCNP: Risk Evaluation and Mitigation Strategies (REMS) Removal and Impact on Care Delivery

Interview with Tabitha Matthews, MSN, APRN-NP, AGACNP-BC, AOCNP: Operational and Educational Needs Following Risk Evaluation and Mitigation Strategies (REMS) Removal

Interview with Joanne Wilson, APRN-NP, DNP: CAR T-Cell Therapy for Solid Tumors

View all

Welcome to the CAR T-Cell Therapy Resource Center! Here you’ll find current information, news items, highlights from the literature, case studies, and other resources that focus on CAR T-cell therapies and the advanced practitioner’s role in delivering high-quality care to our patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Liza Rodriguez, DNP, E-MBA, APRN, AOCNP
APP Manager Hematology/Blood and Marrow Transplant Program
APP Council Chair
Division of Hematologic Malignancies and Cellular Therapeutics
The University of Kansas Cancer Center

Best practice considerations by the American Society of Transplant and Cellular Therapy: Infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies

CAR T-Cell Therapy Resource Center

Interview with Tabitha Matthews, MSN, APRN-NP, AGACNP-BC, AOCNP: Risk Evaluation and Mitigation Strategies (REMS) Removal and Impact on Care Delivery

The EBMT/EHA CAR-T Cell Handbook

SITC Clinical Practice Guideline on Immune Effector Cell-related Adverse Events

ASH-ASTCT COVID-19 Vaccination for HCT and CAR T Cell Recipients: Frequently Asked Questions

Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy

Leukemia and Lymphoma Society: CAR T-Cell Therapy

Transplantation and Cellular Therapy

Best practice considerations by the American Society of Transplant and Cellular Therapy: Infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies

Immunotherapy

The potential of phytomedicines to optimize CAR-T cell therapy in cancer

The New England Journal of Medicine

Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia

Blood Advances

CAR T-cell toxicities: From bedside to bench, how novel toxicities inform laboratory investigations

Transplantation and Cellular Therapy

Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome

Blood

Intrathecal chemotherapy as treatment for chimeric antigen receptor T cell (CAR T) therapy associated neurotoxicity

The Lancet

In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma

Frontiers in Immunology

CAR-T cell therapy clinical trials: Global progress, challenges, and future directions from ClinicalTrials.gov insights

Diagnostics (Basel)

CAR-T cell therapy in ovarian cancer: Where are we now?

EBioMedicine

Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment

Navigating Treatment Adherence in Early-Stage Breast Cancer

Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy in a Patient With Multiple Myeloma

Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy

Fast Facts #12: BCMA Targets